Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab plus chemoradiation with or without olaparib versus durvalumab after chemoradiation in unresectable stage III NSCLC
2019-003237-41Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, olaparib, durvalumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Feb 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003237-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003237-41.